It has been demonstrated that fibrin clots generated from plasma samples obtained from patients with prior thromboembolic events are denser and less susceptible to lysis. Such a prothrombotic fibrin clot phenotype has been suggested as a new risk factor for venous thromboembolism, but its prognostic value is unclear. To assess whether abnormal clot properties can predict recurrent deep vein thrombosis (DVT), we studied 320 consecutive patients aged 18 to 70 years following the first-ever DVT. Plasma clot properties were evaluated after 3 months of anticoagulant treatment since the index event. A mean duration of anticoagulation was 10 months (range, 4-20). Recurrent DVT was observed in 77 patients (25%; 6.6%/year) during a median follow-up of 44 months. Recurrences of DVT were associated with faster formation (-9% lag phase) of denser fibrin networks (-12% fibrin clot permeability [K]) and 4% higher maximum absorbance of plasma clots that displayed impaired fibrinolytic degradation (+25% prolonged clot lysis time [CLT]) and a 5% slower rate of increase in D-dimer levels during clot degradation (D-D; all < .05). Proximal DVT alone, higher C-reactive protein, D-dimer, peak thrombin, lower K shorter lag phase, decreased D-D, and prolonged CLT were independent predictors of recurrences (all < .05). Individuals characterized by low K (≤7.3 × 10 cm) and prolonged CLT (>96 min) were at the highest risk of recurrent DVT (odds ratio, 15.8; 95% confidence interval, 7.5-33.5). Kaplan-Meier curves showed that reduced K and prolonged CLT predicted recurrent DVT. We demonstrate that unfavorably altered clot properties may predict recurrent DVT after anticoagulation withdrawal.
Download full-text PDF |
Source |
---|---|
http://dx.doi.org/10.1182/blood-2017-07-798306 | DOI Listing |
Wiad Lek
December 2024
PROVINCIAL HOSPITAL NAMED AFTER SAINT LUKE, TARNOW, POLAND.
Injectable platelet-rich fibrin (i-PRF) is a novel platelet concentrate that has been employed in dentistry with the objective of promoting tissue regeneration and healing. In contrast to platelet-rich plasma (PRP), i-PRF is more straightforward to handle, more cost-effective, and free from anticoagulants, which reduces biochemical alterations. The i-PRF procedure was developed in 2014 by adjusting the centrifugation forces.
View Article and Find Full Text PDFAm Surg
December 2024
Department of Surgery, University of Kansas Medical Center, Kansas City, KS, USA.
Viscoelastic hemostatic assays (VHAs) have become a valuable tool in guiding transfusion therapy, particularly in trauma care. While various forms of VHA exist, all provide a quantitative assessment of clot kinetics, strength, and dissolution. Studies have demonstrated that VHA can reduce both mortality and utilization of blood products in the general population.
View Article and Find Full Text PDFToxicol Rep
December 2024
Department of Pharmacy, Bangabandhu Sheikh Mujibur Rahman Science and Technology University, Gopalganj 8100, Bangladesh.
This study aimed to evaluate the clot-lysing and membrane stabilizing capacities of ascorbic acid (AA) using and methods. For this, we used clot lysis and hemolyzing tests to check the anti-atherothrombosis and membrane-stabilizing properties of AA, respectively. Additionally, molecular docking studies were performed to investigate AA's interactions with cyclooxygenase-1 (COX-1) and plasminogen enzymes.
View Article and Find Full Text PDFHeliyon
December 2024
Department of Pharmaceutical Chemistry, Faculty of Pharmacy, University of Dhaka, Dhaka, 1000, Bangladesh.
ACS Appl Mater Interfaces
December 2024
Department of Biomedical Engineering, University of Calgary, Calgary, Alberta T2N 1N4, Canada.
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!